PLaN Therapeutics Announces Exclusive License Agreement for Allele-specific siRNA Therapy for PLN-R14del Cardiomyopathy
PLaN Therapeutics has secured an exclusive license to advance allele-specific siRNA sequences into a therapy for PLN-R14del genetic cardiomyopathy, marking a key milestone toward clinical development for this currently untreatable disease. Amsterdam, the Netherlands – January 22, 2026 – PLaN Therapeutics, a nonprofit biotechnology company fully owned by the PLN Foundation, today announced that they […]
PLaN Therapeutics Announces Research Collaboration and License Agreement with UMass Chan Medical School to Advance First-In-Class Allele-specific siRNA Therapy for PLN-R14del Cardiomyopathy
The collaboration will allow PLaN Therapeutics to advance an allele-specific siRNA for the treatment of inherited PLN-R14del cardiomyopathy, an orphan disease Amsterdam, the Netherlands and Worcester, Massachusetts – January 22, 2026 – PLaN Therapeutics, a nonprofit biotechnology company fully owned by the PLN Foundation and focused on developing disease-modifying therapies for PLN-R14del cardiomyopathy, today announced […]
The PLN Foundation becomes the owner of biotech start-up PLaN Therapeutics B.V.
Since the start of the PLN foundation the goal has been to find a safe and affordable treatment for PLN-R14del. Thanks to the tireless efforts of the team, the scientists, and the volunteers connected to the foundation, this treatment is coming closer every day. For that reason, the PLN foundation recently became the owner of […]